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Two novel phosphatidylinositol-4-phosphate 5-kinase type Iγ splice
variants expressed in human cells display distinctive cellular targeting
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The generation of various phosphoinositide messenger molecules
at distinct locations within the cell is mediated via the
speciﬁc targeting of different isoforms and splice variants of
phosphoinositide kinases. The lipid messenger PtdIns(4,5)P2
is generated by several of these enzymes when targeted to
distinct cellular compartments. Several splice variants of the
type Iγ isoform of PIPK (PtdIns4P 5-kinase), which generate
PtdIns(4,5)P2, have been identiﬁed, and each splice variant is
thought to serve a unique functional role within cells. Here, we
have identiﬁed two novel C-terminal splice variants of PIPKIγ
in human cells consisting of 700 and 707 amino acids. These
two splice variants are expressed in multiple tissue types and
display PIPK activity in vitro. Interestingly, both of these novel
splice variants display distinct subcellular targeting. With the
addition of these two new splice isoforms, there are minimally
ﬁve PIPKIγ splice variants that have been identiﬁed in mammals.
Therefore, we propose the use of the HUGO (Human Genome
Organization) nomenclature in the naming of the splice isoforms.
PIPKIγ_i4(700aminoacids)ispresentinthenucleus,atargeting
patternthathasnotbeenpreviouslyobservedinanyPIPKIγ splice
variant. PIPKIγ_i5 (707 amino acids) is targeted to intracellular
vesicle-like structures, where it co-localizes with markers of
several types of endosomal compartments. As occurs with other
PIPKIγ splice variants, the distinctive C-terminal sequences
of PIPKIγ_i4 and PIPKIγ_i5 may facilitate association with
unique protein targeting factors, thereby localizing the kinases
to their appropriate cellular subdomains for the site-speciﬁc
generation of PtdIns(4,5)P2.
Key words: cadherin, endosomal trafﬁcking, phosphatidyl-
inositol 4,5-bisphosphate [PtdIns(4,5)P2], phosphatidylinositol-
4-phosphate 5-kinase type Iγ (PIPKIγ), splice variant.
INTRODUCTION
The signalling pathways that utilize members of the PtdInsPn
family of lipids to transduce messages from one functional com-
plex to another are as distinct as they are complex. PtdIns(4,5)P2
is positioned at the crossroads of many of these signalling
cascades,asitmaybemetabolizedbyphospholipaseCtogenerate
Ins(1,4,5)P3 and 1,2-diacylglycerol, further phosphorylated at the
3-position of the inositol ring by phosphatidylinositol 3-kinase
to generate PtdIns(3,4,5)P3 [1] or used directly as a messen-
ger molecule by binding to proteins containing PH (pleckstrin
homology), PX (phox homology), FERM (band 4.1, ezrin,
radixin, moesin) or comparable domains [1,2]. However, the
method of PtdIns(4,5)P2 generation utilized in these pathways
results in its availability being far from ubiquitous. Rather,
PtdIns(4,5)P2 seems to be synthesized in a highly site-speciﬁc
manner at distinct subcellular locales where it is directly
utilized as a signalling molecule, thereby modulating the activity,
conformation, assembly or disassembly of proteins at these sites
[1,3,4]. The spatial and temporal metabolism of PtdIns(4,5)P2
has emerged as a crucial regulator of multiple cellular processes,
including actin reorganization [1,5,6], focal-adhesion dynamics
[1,7–9], endocytosis and exocytosis [4,10–19], nuclear signalling
pathways [20,21] and gene expression [22].
Most cellular PtdIns(4,5)P2 generation is fulﬁlled by the α,
β and γ isoforms of the type I PIPKs (PtdIns4P 5-kinases).
Althoughretaininghighhomologywithinthelipidkinasedomain,
each isoform exhibits a distinct subcellular localization pattern
and functional speciﬁcity [23]. It is believed that the N- and
C-terminal sequence divergence of each PIPKI isoform
contributes to this diversity in targeting and function. PIPKIα
participates in both nuclear and cytoplasmic PtdIns(4,5)P2
generation, where it has been implicated in the regulation
of RNA polyadenlyation machinery and growth-factor-induced
reorganization of the cytoskeletal superstructure [3,24]. The
cellularrolesofPIPKIβ arelessdeﬁned,butafunctionforPIPKIβ
in actin assembly and endocytosis has been suggested [1,3,23].
The newest member of the type I family, PIPKIγ (type Iγ
PIPK), is a workhorse for site-speciﬁc PtdIns(4,5)P2 generation
in a plethora of cytoplasmic processes. PIPKIγ is a fundamental
regulator of the assembly and disassembly of sites of cell-
matrix [1,8,9] and cell–cell interaction [17,25] termed focal
adhesions and adherens junctions respectively. Importantly, the
human PIPKIγ is known to encode at least two alternative
splice variants, PIPKIγ640 and PIPKIγ668 [26]. These splice
variants differ by the inclusion of exon 17, which encodes
a 28-amino-acid C-terminal extension speciﬁc to PIPKIγ668
[26]. This 28-amino-acid extension has been demonstrated to
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Human Genome Variation Society; His6, hexahistidine; HUGO, Human Genome Organization; LAMP1, lysosomal-associated membrane protein 1; PIPKIγ,
type Iγ isoform of PtdIns4P 5-kinase; RACE, rapid ampliﬁcation of cDNA ends; SC-35, splicing factor, arginine/serine-rich 2; siRNA, small interfering RNA;
TfnR, transferrin receptor; UTR, untranslated region.
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The mRNA and peptide sequences of PIPKIγ_v4 and PIPKIγ_v5, including the sequenced region of each splice variant’s 3 -UTR (untranslated region)
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Table 1 Summary of proposed revisions to PIP5K1C splice variant nomenclature
Human nomenclature Mouse nomenclature Corresponding exons (human) HUGO mRNA nomenclature HGVS‡ protein nomenclature
PIPKIγ640, PIPKIγ87, PIPkinIγb PIPKIγ635, PIPKIγ87, PIPkinIγb 1–16a, 18 PIPKIγ_v1 PIPKIγ_i1
PIPKIγ668, PIPKIγ90, PIPkinIγa PIPKIγ661/662, PIPKIγ90, PIPkinIγa 1–16a, 17, 18 PIPKIγ_v2 PIPKIγ_i2
* PIPKIγ93, PIPkinIγc 1–16a, 16c†, 17, 18 PIPKIγ_v3 PIPKIγ_i3
PIPKIγ700 * 1–16a, 16b, 16c PIPKIγ_v4 PIPKIγ_i4
PIPKIγ707 * 1–16a, 16c PIPKIγ_v5 PIPKIγ_i5
* Splice variant not deﬁned.
† Partial exon.
‡HGVS, Human Genome Variation Society.
confer speciﬁc subcellular targeting and function on PIPKIγ668,
where it consequently regulates focal adhesion dynamics,
EGF (epidermal growth factor)-stimulated directional migration,
basolateral targeting of E-cadherin, and endocytosis of the
TfnR (transferrin receptor) [8,9,13,14,16–18,27]. Aside from
mediating speciﬁc protein–protein interactions, this extension
also affords several methods of regulating PIPKIγ668 activity,
as it is tyrosine- and serine-phosphorylated by Src [28] and
cyclin-dependent kinase [29] respectively. In addition, PIPKIγ
can be directly phosphorylated by EGFR (EGF receptor) [27].
These phosphorylation events are in turn antagonized by speciﬁc
phosphatases [29,30]. In the absence of a speciﬁc C-terminal
extension, PIPKIγ640 also plays a speciﬁc cellular role, as it is
the major contributor of the PtdIns(4,5)P2 utilized in G-protein-
coupled-receptor-mediated Ins(1,4,5)P3 generation [31].
A third PIPKIγ splice variant consisting of 688 amino acids
was described in mouse and rat neuronal tissue by Giudici et al.
[32, 33]. In addition to containing the 28-amino-acid C-terminal
extension of PIPKIγ668, this novel splice variant also contained
a unique 26-amino-acid sequence inserted prior to the extension
ﬁrst deﬁned in PIPKIγ668 and appears to be neuronal-speciﬁc
[32].AlthoughGiudicietal.uncoveredthepresenceofasequence
homologous with this insertion in the human genome, they did
not conﬁrm its existence in human tissues [32]. Here, we provide
evidence that two unique PIPKIγ C-terminal splice variants do
indeed exist in human cells. The two novel splice variants consist
of 700 and 707 amino acids, possess PIPK activity, and are
expressed in a multitude of cell types and tissues. Importantly,
these splice variants display subcellular localization patterns that
are unique from PIPKIγ640 or PIPKIγ668, suggesting that each
splice variant likely ﬁlls a distinct functional role within cells.
Since the discovery of these two new splice variants further
complicates the PIPKIγ nomenclature, all further instances of
PIP5K1C gene products mentioned in the present paper have
been assigned nomenclature based on the guidelines established
by the Genetic Nomenclature Committee of HUGO (Human
Genome Organization) (Table 1). Following this convention,
the unique PIPKIγ mRNAs described herein are referred to as
PIPKIγ_v4 and PIPKIγ_v5, whereas their protein products are
termed PIPKIγ_i4 and PIPKIγ_i5.
EXPERIMENTAL
Cloning of PIPKIγ splice variants
mRNA from mammary epithelial cell line MCF10A was
isolated using the Micro-FastTrack
TM 2.0 mRNA Isolation Kit
(Invitrogen). 3
 -RACE (3
  rapid ampliﬁcation of cDNA ends) was
performed with the GeneRacer system (Invitrogen) using primers
speciﬁctoaportionofPIPKIγ exon16(5
 -GCCTCTGCTGCTG-
TTGAAGTAGAAA-3
 ) and the supplied 3
  adaptor primer
according to the manufacturer’s instructions. PCR products were
run on agarose gels, and individual DNA bands were excised,
puriﬁed and ligated into the pGEM-T Easy Vector (Promega).
Full-length PIPKIγ_v4 and PIPKIγ_v5 were ampliﬁed from
MCF10A cDNA using the 5
  primer (5
 -ATGGAGCTGGAGGT-
ACCGGA-3
 )a n d3
  primer (5
 -TTACCCAAAGCCCTTCTGG-
AAA-3
 ).
Expression constructs
Human PIPKIγ splice variants were ampliﬁed via PCR for
insertion into the pCMV-HA vector (Clontech). Upon insertion
into expression vectors, the 3
 -UTR (untranslated region) of
each PIPKIγ splice variant was removed. For expression in
Escherichia coli, PIPKI coding sequences were subcloned into
pET28 (Novagen). PIPKIγ point mutations were generated using
PCRprimeroverlapextensionwithprimerscontainingthedesired
mutations.
Antibodies
Polyclonal antibodies towards the PIPKIγ splice variants were
created as previously described [8]. Anti-HA (haemagglutinin)
monoclonal antibody HA.11 was obtained from Covance.
Rabbit polyclonal anti-HA and anti-(lamin β1) were purchased
from Santa Cruz Biotechnology. Anti-β-tubulin, anti-N-
cadherin, anti-E-cadherin, anti-α-adaptin, anti-TfnR, anti-EEA1
(early endosome antigen 1) and anti-SC-35 (splicing factor,
arginine/serine-rich 2) antibodies were purchased from BD
Biosciences, and anti-actin antibody was obtained from MP
Biomedicals. Anti-nucleolin and anti-CD63 antibodies were
obtained from Millipore. Anti-LAMP1 (lysosomal-associated
membrane protein 1) monoclonal antibody was from Abcam,
and anti-talin was from Sigma–Aldrich. Alexa 350-, Alexa
488-, Alexa 555-, Alexa 647- and Paciﬁc Blue-conjugated
secondary antibodies were purchased from Molecular Probes.
Secondary horseradish-peroxidase-conjugated antibodies for
Western blotting were obtained from Jackson Immunoresearch
Laboratories.
Puriﬁcation of recombinant protein
PIPKI coding regions subcloned into the pET28 vector were
transformed into E. coli Rosetta
TM 2(DE3) competent cells from
Novagen. Overnight starter cultures were expanded in 0.5 litre
cultures in Luria Broth to an attenuance (D600)o f0.6 and were
then induced with 1 mM isopropyl β-D-thiogalactoside for 3 h at
37◦C with agitation. His6 (hexahistidine)-tagged fusion proteins
were then puriﬁed from E. coli lysates with His-Bind
TM resin
(Novagen) according to the manufacturer’s instructions.
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PIPKI lipid kinase activity assay
The lipid kinase activity of PIPKI was assayed against 25 μM
PtdIns4P micelles or Folch Brain Extract as previously described
[17,34].
Subcellular fractionation
HeLa cells were plated at 1.3×10
6/10-cm-diameter plate and
grown overnight. Cells were lifted with a non-enzymatic cell
dissociation buffer (Sigma–Aldrich), collected by centrifugation
(1000 g for 5 min at 4◦C ) ,a n dw a s h e dt w i c ei nc o l dP B S .O n e
half of the cell pellet was lysed directly in 2×loading buffer
[1×loading buffer is 10 mM Tris, 5% (v/v) glycerol, 1% (w/v)
SDS and 1% (v/v) 2-mercaptoethanol, pH 6.8] as a whole-cell
lysate control. The remainder of the cells were resuspended
in 300 μl Buffer A [10 mM Hepes, pH 7.9, 1.5 mM MgCl2,
10 mM KCl and 0.5 mM DTT (dithiothreitol)], vortex-mixed
brieﬂy and incubated on ice for 30 min. After the addition of
0.2% (v/v) Nonidet P40, cell lysis was veriﬁed by Trypan Blue
exclusion and cells were then centrifuged at 300 g for 15 min
at 4◦C. The cytoplasmic fraction was removed and the pellet
containing nuclei was lysed for 30 min at 4◦C in 100 μlo f
buffer C [20 mM Hepes, 25% (v/v) glycerol, 450 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA and 0.5 mM DTT]. The nuclear
lysate was then cleared by centrifugation at 16000 g for 15 min
at 4◦C. The cytoplasmic, nuclear and whole-cell lysates were
then quantiﬁed with Bradford’s reagent (25 ml of phosphoric
acid, 12.5 ml of ethanol and 25 mg of Coomassie Brilliant Blue;
Bio-Rad Laboratories) before Western blotting.
Cell culture and transfection
HeLa cells plated at 5.5×10
5 cells/60-mm-diameter plate in
10% (v/v) fetal bovine serum+Dulbecco’s modiﬁed Eagle’s
medium were incubated overnight before transfection with 8 μg
of total DNA and 9 μl of Lipofectamine
TM 2000 (Invitrogen).
Cells were harvested for analysis at about 18 h post-transfection.
ForsiRNA(smallinterferingRNA)knockdownofPIPKIγ,HeLa
cells were transfected with Lipofectamine
TM 2000 and either
a non-targeting or pan-PIPKIγ siRNA duplex (GCCACCUU-
CUUUCGAAGAA) and harvested at either 48 or 72 h post-
transfection.
Immunoﬂuorescence and confocal microscopy
MCF10A and HeLa cells were grown on glass coverslips placed
inside six-well plates 24 h prior to transfection. Coverslips
containing cells were washed in PBS at 37◦C ,a n dt h e nﬁ x e dw i t h
chilled methanol or 4% (w/v) paraformaldehyde, followed by
permeabilization with 0.5% (v/v) Triton X-100 in PBS. The cells
werethenblockedfor1 hatroomtemperature(25◦C)in3%(w/v)
BSA (Jackson Immunoresearch Laboratories) in PBS. Primary-
antibody incubation was performed at 37◦C for 2 h or 4◦Cf o r
16 h, whereas incubation with ﬂuorophore-conjugated secondary
antibodies was performed at 37◦C for 30 min. Cells were washed
inbetweenincubationstepswith0.1%(v/v)TritonX-100inPBS.
Indirect immunoﬂuorescence microscopy was performed on a
NikonEclipseTE2000UinstrumentequippedwithaPhotometrics
CoolSNAP CCD (charged coupled device) camera. Images were
captured and further processed using MetaMorph (Molecular
Devices) or AutoQuant (Media Cybernetics) cellular imaging
software. Images were exported to Photoshop CS2 (Adobe) for
ﬁnal processing and assembly.
Tissue and cell-line immunoblotting
Mouse tissue was excised from a CO2-asphyxiated C57BL/6
female mouse and ﬂash-frozen in liquid nitrogen. Proteins were
extracted from tissues by grinding with a tissue homogenizer
into a buffer consisting of 20 mM Tris/HCl, pH 7.6, 1% (v/v)
Triton X-100, 137 mM NaCl, 2 mM EDTA, 1 mM Na3VO4,
1 mM DTT and protease inhibitors. Tissue homogenates were
rotated for 2 h at 4◦C to complete lysis. Lysates were cleared
of tissue debris by centrifugation at 15000 g for 20 min
at 4◦C. Protein concentrations were calculated using the
BCA (bicinchoninic acid) protein quantiﬁcation assay (Bio-Rad
Laboratories) according to the manufacturer’s instructions. For
Western blotting of mouse tissue lysates, 20 μg of each tissue
lysate was subjected to SDS/7.5%-(w/v)-PAGE. Cell line lysates
were generated by scraping a 100-mm-diameter plate of each cell
type into 1 ml of RIPA buffer [50 mM Tris/HCl, 150 mM NaCl,
1.0% (v/v) Nonidet P40, 0.5% (w/v) sodium deoxycholate,
1.0 mM EDTA and 0.1% (w/v) SDS, pH 7.4), supplemented
with protease inhibitors, followed by incubation for 1 h at 4◦C.
Lysates were cleared, quantiﬁed and 15 μg of each cell line lysate
was analysed by Western blot as described above. A PageRuler
PrestainedProteinLadder(Fermentas)oraBenchmarkPrestained
Protein Ladder (Invitrogen) was used as the molecular-mass
standard for Western blotting.
RESULTS
Identiﬁcation of PIPKIγ mRNAs in MCF10A human epithelial cells
The human PIPKIγ mRNA that encodes PIPKIγ_i1 or
PIPKIγ_i2 contains 17 or 18 exons respectively, with exon 18
consisting of the translational stop codon for both proteins as well
as a long 3
 -UTR region (∼3 kb) (Figure 1B). When Western-
blotting cell lysates from MCF10A cells were incubated with
a pan-PIPKIγ antibody, an immunoreactive band was observed
at a slightly greater molecular size than that attributable to
PIPKIγ_i2. This provided evidence that there may be other
PIPKIγ splice variants that have yet to be identiﬁed. In order to
identify the putative novel PIPKIγ species in MCF10A epithelial
cells, mRNA was extracted from cells and subjected to reverse
transcription–PCR. Initially, any unidentiﬁed splice variant was
expected to share exon 18 as a 3
 -UTR. In subsequent PCRs,
primers were used that targeted internal exons, along with a
primer targeting the 3
 -UTR, to amplify PIPKIγ mRNAs. These
amplicons were subcloned into a T/A cloning vector and ∼50
clonesperregionwerescreenedviarestriction-enzymedigestand
DNA sequencing for variations in exon structure. Although some
variationofexonstructurewasobserved(Figure1Bandresultsnot
shown), each alternative splicing event that was detected by this
method resulted in a transcript that was shorter than PIPKIγ_v2.
Because the immunoreactive band we had observed in MCF10A
lysateswasofgreatermolecularsize,thesesmallersplicevariants
were not characterized further.
Since the previously described splice variants of PIPKIγ
displayalternativesplicingofthe3
  endoftheirmRNAtoencodea
unique C-terminal tail region, we hypothesized that the unknown
splice variant may contain a longer unique C-terminus distinct
from that of PIPKIγ_i2. The PIPKIγ gene is quite long, being
over 70 kb in length (chromosome 19; 3 581 182–3 651 445);
however, the mRNA which encodes PIPKIγ_v2 is only ∼5k b .
Although this is not uncommon, it leaves the possibility that other
splicing events can incorporate sequences that are assumed to
be intronic. Interestingly, introns 16–17 of the human PIPKIγ
sequence, which in PIPKIγ pre-mRNA lies between the majority
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.476 N. J. Schill and R. A. Anderson
Figure 1 The human PIPKIγ gene encodes at least four C-terminal splice variants
(A) The full-length PIPKIγ_v4 and PIPKIγ_v5 transcripts were ampliﬁed from MCF10A-epithelial-cell cDNA using a primer targeted to the conserved 5 -end of the PIPKIγ transcript and a second
primer matching the putative 3  alternatively spliced exon identiﬁed via 3 -RACE. The less prominent band running immediately below PIPKIγ_v5 was also sequenced and found to be non-speciﬁc.
(B) A revised exon map of the human PIPKIγ gene illustrates the four major C-terminal splice variants that have been identiﬁed. The overall lengths of PIPKIγ transcripts listed are approximate
estimates based on the deﬁned open reading frames plus the 3  untranslated region. Two novel exons, which have been termed exon 16b and 16c, make up the alternatively spliced C-termini of
the PIPKIγ_v4 and PIPKIγ_v5 transcripts. Interestingly, the PIPKIγ_v4 transcript is longer than that of PIPKIγ_v5, but PIPKIγ_v4 mRNA encodes a shorter protein, owing to a stop codon in exon
16b. PIPKIγ transcripts were identiﬁed in our initial experiments that lacked portions of exons 3 or 5, or all of exon 14, but these splice variants were not further characterized. (C) CLUSTALW
alignment of the C-terminal amino acid residues of the four PIPKIγ splice variants. Note that part of the C-terminus of PIPKIγ_i5 (W647IYSPRH653) is similar to the C-terminus of PIPKIγ_i2
(W647VYSPLH653). The presence of a full stop (period) indicates the lack of a corresponding amino acid residue at the indicated position.
of the PIPKIγ coding sequence and the 84 bp which encode the
unique C-terminus of PIPKIγ_i2, is also quite large (∼5.3 kb).
If another PIPKIγ C-terminal splice variant were encoded by
the PIPKIγ gene, it is likely that this intron would contain the
source sequence for the unique extension. With this in mind, we
performed 3
 -RACE on MCF10A cDNA using a forward primer
directed towards exon 16. The amplicons were then analysed by
agarose-gel electrophoresis, individual bands were extracted for
ligation into a T/A vector, and the ligated inserts were sequenced.
The sequence information obtained from 3
 -RACE indicated the
presence of a previously unidentiﬁed exon mapping to intron
16–17 (3 589 519–3 589 881) of the PIPKIγ gene. PCR was
then performed to amplify the full-length splice variant using a
primer directed towards the known start codon of PIPKIγ and the
predicted stop codon and its 5
  ﬂanking sequence. This resulted
in the identiﬁcation of two splice variants containing the novel
exon, which we have named according to HUGO guidelines as
PIPKIγ_v4 and PIPKIγ_v5 (Table 1; Figure 1A). PIPKIγ_v4
was predicted to contain a reading frame of 2103 nucleotides,
whereasthereadingframeofPIPKIγ_v5wasexpectedtocontain
2124 nucleotides (Figure 1B). Interestingly, both splice variants
utilize the novel exon 16c. In the case of PIPKIγ_v5, this exon
encodes a unique 67-amino-acid C-terminus. By contrast, the
unique C-terminus of PIPKIγ_v4 is encoded by a second novel
exon, 16b, whereas exon 16c makes up a portion of its 3
 -UTR.
Upon identiﬁcation of the splice variant mRNAs in MCF10A
cells, we then sought to determine whether these messages were
evolutionarily conserved.
The coding regions of PIPKIγ_v4 and PIPKIγ_v5 are evolutionarily
conserved
The PIPKIγ_v2 splice variant has been conserved through
evolution, as the DNA sequence encoding its distinctive
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Novel PIPKIγ splice variants display distinctive cellular targeting 477
Figure 2 PIPKIγ_i4 and PIPKIγ_i5 are evolutionarily conserved
ACLUSTALWalignmentofputativeorthologuesofPIPKIγ_i4andPIPKIγ_i5wascreatedusingsequenceinformationintheENSEMBLdatabase.TheC-terminalaminoacidsequencesofPIPKIγ_i4
and PIPKIγ_i5 were used to search the ENSEMBL sequence database for potential matches in other species. Key to species not already identiﬁed: C. familiaris, Canis familiaris (dog); G. gallus,
Gallus gallus (chicken); H. sapiens, Homo sapiens (man); M. musculus, Mus musculus, house mouse; R. norvegicus, Rattus norvegicus, Norway rat.
28-amino-acid C-terminal extension is present in most
vertebrates, with a high level of conservation within mammals
[1,26,32]. This conservation underlines the importance of this
splice variant in multiple cellular functions. Using the unique
C-terminal amino acid sequences of human PIPKIγ_i4 and
PIPKIγ_i5, a thorough BLASTN search was performed of both
the complete and incomplete genome assemblies available on
ENSEMBL. Putative orthologues of PIPKIγ_i5 were identiﬁed
in multiple vertebrate species, indicating that the function
of PIPKIγ_i5 is most likely conserved (Figure 2). Interestingly,
PIPKIγ_i4orthologueswereidentiﬁedinMacacamulatta(rhesus
macaque monkey) and Pan troglodytes (chimpanzee), but our
search of translated sequence databases did not yield PIPKIγ_i4
orthologues in the other species where sequence information
was available. In contrast with this ﬁnding, the presence of the
PIPKIγ_i4 protein was observed in canine, mouse and rat cell
lines via Western blot (see below; Figure 3D). Since a full
assembly of the mouse genome has recently been completed
[35], we searched the mouse PIPKIγ gene for the PIPKIγ_v4
codingsequence.Wedidobserveanucleotidesequenceinintrons
16–17 of the mouse PIPKIγ gene that partially matches the
human PIPKIγ_v4 coding sequence. However, we have not been
able to translate this sequence into a putative version of the
mouse PIPKIγ_i4 protein, owing to apparent gaps in the geno-
mic sequence. Our unsuccessful attempts to identify the mouse
PIPKIγ_i4orthologuereinforcethenotionthatthemousegenome
assembly may require localized review and revision [35].
PIPKIγ_v4 and PIPKIγ_v5 are expressed as human cellular
proteins
To verify that these unique messages were expressed in human
cells as proteins, polyclonal antibodies were made to speciﬁcally
detect each of the novel splice variants. Recombinant peptides
corresponding to each C-terminus of the novel splice variants
(Figure 1C) were used to immunize rabbits, and antibodies were
afﬁnity-puriﬁed from bulk sera over an antigen column. These
antibodies were analysed by Western blotting HeLa cell lysates
transfected with each of the PIPKIγ splice variant constructs
(Figure 3A). The antibodies speciﬁcally detected their target
splice variant, with no evident cross-reactivity with other PIPKIγ
splice variants. The speciﬁcity of these antibodies was further
conﬁrmed by siRNA knockdown of total cellular PIPKIγ and
Western blotting (Figure 3B). The results of these Western blots
conﬁrm that the band detected by each splice variant antibody is
the intended target protein.
With functional and speciﬁc polyclonal antibodies towards
PIPKIγ_i4 and PIPKIγ_i5, we were then able to Western-blot
epithelial and ﬁbroblast cell line lysates from human, mouse,
rat and canine cells. As shown in Figure 3(C), each cell line
tested via Western blot expressed both the PIPKIγ_i4 and
PIPKIγ_i5 splice variants, with an apparent molecular mass
of approx. 100 kDa. Since these splice variants are detectable
in human, canine, mouse and rat cell lines, this conﬁrms that
the expression of PIPKIγ_i4 and PIPKIγ_i5 is evolutionarily
conserved within mammals. Interestingly, PIPKIγ_i4 appears
as a tight doublet in some cell lines. PIPKIγ_i2 also appears as
severaldiscretebandsviaWesternblotting,andthismaybedueto
the phosphorylation events that occur on its C-terminus [27–29].
Therefore, PIPKIγ_i4 may undergo phosphorylation or other
post-translationalmodiﬁcationsthataffectsitsapparentmolecular
mass.
To determine the tissue distribution of these splice variants,
20 μg of C57BL/6 mouse tissue lysates was Western-blotted
with each of the anti-(splice-variant) antibodies as well as the
anti-pan-PIPKIγ antibody. As shown in Figure 3(D), each of
the PIPKIγ splice variants displays a distinct expression pattern
in mouse tissue. Consistent with previous reports, PIPKIγ_i2 is
most strongly expressed in brain tissue [26,32,36], but is also
expressed in greater quantities in the heart and lungs. PIPKIγ_i4
is strongly expressed in the pancreas and liver, but is also present
inlesserquantitiesinthebrain,heart,lungandkidney.PIPKIγ_i5
is present in large amounts in the heart and large intestine, but is
also present in the lung, pancreas and thyroid, and, to a lesser
extent, brain, stomach and kidney. Interestingly, the apparent
molecular mass of the PIPKIγ_i5 mouse orthologue is approx.
5–10 kDa lower than that of the human form. This size shift
could be the result of a second alternative splicing event that has
removed a portion of the mouse PIPKIγ_i5 mRNA. In mouse
brain tissue lysates, two bands appear that are immunoreactive to
the anti-PIPKIγ_i5 polyclonal antibody, but neither corresponds
to the major species of PIPKIγ_i5 observed in other mouse
tissues (Figure 3D). It is possible that the lower band is the
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Figure 3 PIPKIγ_v4 and PIPKIγ_v5 transcripts are expressed as proteins
(A)ThespeciﬁcityofpuriﬁedpolyclonalantibodiestowardtheuniqueC-terminalsplicevariantsofPIPKIγ wastestedviaWesternblot.HA-taggedPIPKIγ constructsweretransfectedintoHeLacells,
andWesternblotsofwhole-celllysateswereprobedwithsplicevariant-speciﬁcanti-PIPKIγ polyclonalantibodies.(B)Toverifythattheanti-PIPKIγ polyclonalantibodiescanrecognizeendogenous
proteinandarespeciﬁctowardstheirintendedsplicevariant,totalPIPKIγ wasknockeddowninHeLacellsusingsiRNAfor48or72h.CelllysateswereWestern-blottedusingeachoftheanti-PIPKIγ
polyclonal antibodies, and anti-actin antibody was used as a loading control. (C) Expression of PIPKIγ splice variants in several mammalian cell lines was determined by Western-blotting cell line
lysateswithanti-PIPKIγ antibodies.Anti-actinantibodywasusedasaloadingcontrol.(D)FreshtissuewasextractedfromaC57BL/6mouse,lysed,andtotalsolubleproteinwasquantiﬁed.A20 μg
portion of lysate was subjected to Western blotting with the anti-PIPKIγ polyclonal antibodies to determine the tissue distribution of splice variants. Abbreviations: Ctrl., control; HA-Iγ, HA-tagged
PIPKIγ; IB:, immunoblot; Iγ_i5 (etc.), PIPKIγ_i5; Lrg. Int., lareg intestine; pan-Iγ, pan-PIPKIγ; Transfect., transfection. i_5 etc. designates the protein, whereas v_5 designates the mRNA.
brain-speciﬁc PIPKIγ splice variant (PIPKIγ_i3), identiﬁed by
Giudici et al. [32,33], which shares partial sequence homology
with the human PIPKIγ_i5 variant described here [32,33]. The
upper band is approx. 100 kDa, and, in view of its molecular
mass, is potentially the full mouse orthologue of PIPKIγ_i5.
Importantly, the expression proﬁles of each of the PIPKIγ splice
variants are indicative of a specialized role for each of these
proteins in a particular tissue.
PIPKIγ_i4 and PIPKIγ_i5 possess lipid kinase activity towards
PtdIns4P
The type-I PIPKs synthesize PtdIns(4,5)P2 using the cellular pool
ofPtdIns4Passubstrate[1,3,23].Thisreactioncanbereproduced
in vitro using recombinant or immunoprecipitated PIPKI enzyme
and PtdIns4P-containing micelles or liposomes [34]. The kinase
domains of PIPKIγ_i4 and PIPKIγ_i5 are identical in sequence
composition with that of the previously characterized PIPKIγ
splice variants. However, we wanted to explore whether the
additional amino acids present at the C-terminus of PIPKIγ_i4
and PIPKIγ_i5 affected the activity of the enzymes towards
PtdIns4P. To test this, an in vitro kinase activity assay was done
using His6-tagged recombinant PIPKIγ splice variants or PIPKIα
(positive control), PtdIns4P micelles, and [γ-
32P]ATP. As shown
Figure 4 PIPKIγ splice variants display PtdIns(4)P 5-kinase activity
Either 1μg( 1 X )o r5μg( 5 X )o fH i s 6-tagged recombinant PIPKIα or PIPKIγ splice variants
were added to PtdIns4P micelles and [γ-32P]ATP for 5 min at room temperature to test in vitro
PIPK activity, and lipids extracted from the reaction mixtures were separated by TLC. Puriﬁed
BSA was incubated under the same conditions as a control.
in Figure 4, no apparent differences in the in vitro kinase activity
towards PtdIns4P exist between the four enzymes. This result
was conﬁrmed by substituting Folch Brain Extract as substrate
in these assays (results not shown) [9]. These results suggested
that, at least in vitro, the C-terminal extensions of PIPKIγ splice
variants do not directly have an impact on the kinase activity of
the enzymes.
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Novel PIPKIγ splice variants display distinctive cellular targeting 479
PIPKIγ_i4 is a nuclear-targeted splice variant
The 28-amino-acid C-terminal extension that is present on
PIPKIγ_i2 is directly responsible for the targeting of this splice
variant to focal adhesions in mesenchymal cells and to cell–cell
contacts in polarized epithelial cells. This occurs via the associ-
ation of this unique C-terminus with talin or E-cadherin and AP
(adaptor protein) complexes [8,9,17,27,28]. Therefore, it is likely
that the unique C-terminal PIPKIγ variants described here also
facilitate protein–protein interactions which target each splice
variant to a discrete location within the cell.
Toexplorethesubcellulartargetingofthesenewsplicevariants,
we stained cells with polyclonal antibodies to pan-PIPKIγ,
PIPKIγ_i4 and PIPKIγ_i5. Unfortunately, the PIPKIγ_i5
polyclonal antibody resulted in very poor staining in all cell lines
tested.WhenMCF10Acellswerestainedwithaanti-pan-PIPKIγ
polyclonal antibody, we observed PIPKIγ localization largely at
cell–cellcontactswhereitco-localizeswiththeadhesionmolecule
E-cadherin (Figure 5A). A portion of this staining is likely to be
indicative of PIPKIγ_i2, the functional contribution of which
to E-cadherin biology is well established [4,17]. However, the
anti-pan-PIPKIγ polyclonal antibody also shows some reactivity
towards punctuate nuclear structures (Figure 5A). Interestingly,
our anti-PIPKIγ_i4 polyclonal antibody indicated a localization
of this variant to subnuclear structures, and, to a lesser extent,
the cytoplasm, in MCF10A (Figure 5A), HeLa (Figure 5B),
and NRK (normal rat kidney) cells (results not shown). Another
type-I PIPK, namely PIPKIα, targets to subnuclear sites known
as ‘nuclear speckles’. where it associates with splicing factors
to regulate mRNA processing [22,37]. PIPKIγ_i4 staining co-
localized with SC-35, a marker of nuclear speckles, but not
nucleolin (Figures 5A and 5B). This result is striking, as
PIPKIγ has not been previously identiﬁed as a nuclear PIPKI.
To further assess the targeting of PIPKIγ_i4, HeLa cells were
fractionated into their nuclear and cytosolic components, and
these lysates were subjected to Western blotting with anti-
PIPKIγ polyclonalantibodies.Blottingwiththeanti-pan-PIPKIγ
antibody indicated that PIPKIγ is mainly located in the cytosolic
fraction, but a discernable amount of PIPKIγ was present in
the nuclear fraction as well (Figure 5C). In agreement with the
results from blotting with anti-pan-PIPKIγ antibody, PIPKIγ_i4
was identiﬁed in both the cytoplasmic and nuclear fractions
(Figure 5C). Interestingly, PIPKIγ_i4 appeared as a doublet in
the nuclear, but not cytoplasmic, fraction. This probably indicates
post-translational modiﬁcation of PIPKIγ_i4, which is consistent
with our observations of this splice variant in Figure 3(C). Taken
together, these results support the presence of PIPKIγ_i4 in the
nucleus and suggest that PIPKIγ_i4 could be functionally active
in cytoplasmic as well as nuclear processes.
PIPKIγ_i5 targets to discrete cytoplasmic domains
Asourattemptstoutilizetheanti-PIPKIγ_i5polyclonalantibody
for immunoﬂuorescenve staining were unsuccessful, HA-tagged
PIPKIγ_i5 was expressed in HeLa cells and its localization was
observed. PIPKγ_i5 was found to target to the plasma membrane
as well as to punctuate and enlarged cytoplasmic vesicle-like
structures (Figure 6). To conﬁrm the nature of these structures,
HeLa cells transfected with PIPKIγ_i5 were stained for various
markers of endosomal compartments. PIPKIγ_i5 was found to
partially co-localize with a subset of vesicles that stained positive
forTfnR(recyclingendosomes),EEA1(earlyendosomes),CD63
(multi-vesicular bodies/late endosomes), and, to a lesser extent,
LAMP1 (lysosomes) (Figure 6). As we observed some co-
localizationofPIPKIγ_i5withLAMP1,thiscouldindicateactive
Figure 5 PIPKIγ_i4 is a nuclear-targeted phosphoinositide kinase
(A) MCF10A or (B) HeLa cells were grown on coverslips, ﬁxed in methanol, and probed
with antibodies for pan-PIPKIγ (green), PIPKIγ_i4 (Iγ_i4; green), E-cadherin (ECD) (red),
and SC-35 (red). Co-localization of red and green immunoﬂuorescence channels is indicated
in yellow. DAPI (4 ,6-diamidino-2-phenylindole) staining was omitted from merged images
(Merge)oflabellednuclei.Thescalebarrepresents10μm.(C)Thecytosolic(Cyto)andnuclear
(Nuc) protein fractions of HeLa cells were separated as described in the Experimental section,
thensubjecttoWesternblottingwithanti-PIPKIγ_i4andpan-PIPKIγ antibodies.Laminβ1and
β-tubulin were Western-blotted as controls for the nuclear and cytosolic fractions respectively.
Abbreviation: WCL, whole-cell lysate.
degradation of PIPKIγ_i5. However, degradation of PIPKIγ_i5
was not observed, as treatment of these cells with chloroquine
did not alter PIPKIγ_i5 expression levels (results not shown). As
shown in Figure 6, only a subset of PIPKIγ_i5-positive vesicles
co-localized with any of these endosomal markers. However,
these results suggest that PIPKIγ_i5 may be an active participant
in endosomal trafﬁcking events at multiple locations within the
endosomal system.
PIPKIγ_i5 is functionally distinct from PIPKIγ_i2
Although the C-terminus of PIPKIγ_i4 is quite distinct from that
of the other human splice variants, the C-terminus of PIPKIγ_i5
shows partial similarity to that of PIPKIγ_i2 (Figure 1C). In
particular, the W
647VYSPLH
653 (one-letter amino acid code)
motif present in PIPKIγ_i2 shows a high level of similarity to
the sequence W
647IYSPRH
653 in the C-terminus of PIPKIγ_i5.
In PIPKIγ_i2, this sequence modulates the association of
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Figure 6 PIPKIγ_i5 localizes to endosomal compartments
HeLa cells expressing HA-tagged PIPKIγ_i5 were ﬁxed in paraformaldehyde and stained with
anti-HA (green) and antibodies towards TfnR (recycling endosomes), EEA1 (early endosomes),
CD63 (multi-vesicular bodies/late endosomes) and LAMP-1 (lysosomes) (all in red). Yellow
areas indicate co-localization of red and green immunoﬂuorescence signals. The inset ﬁgures
are 175% zooms of the outlined area. The scale bar represents 10μm.
PIPKIγ_i2 with talin [1] and AP complexes [13,14,16–18,38].
To determine potential PIPKIγ_i5 functional overlap with
PIPKIγ_i2, HeLa cells expressing PIPKIγ_i5 were stained for
endogenoustalinorα-adaptin.PIPKIγ_i5didnotco-localizewith
talin (Figure 7A) or α-adaptin (results not shown) in HeLa cells.
In addition,PIPKIγ_i5 did notco-immunoprecipitate with talin1,
talin2 or α-adaptin (results not shown), conﬁrming that, although
the C-terminus of PIPKIγ_i5 contains this similar sequence, it
does not target to the same cellular domains and probably cannot
functionally compensate for PIPKIγ_i2.
PIPKIγ_i2 directly associates with E-cadherin in polarized
epithelial cells, both at cell–cell contacts and in TfnR-positive
recycling endosomes, and the targeting of E-cadherin to the
plasma membrane by PIPKIγ_i2 requires both PtdIns(4,5)P2
generation and the association of PIPKIγ_i2 with AP1B via its
unique C-terminus [17]. HeLa cells do not express E-cadherin;
instead,cell–cellcontactsinHeLacellsaremediatedbyN-cadhe-
rin, another member of the classical cadherin family. N-cadherin
also directly associates with PIPKIγ via its conserved kinase
domain [17,39] and, as the kinase domain of PIPKIγ_i5 is
identical with that of PIPKIγ_i2, we tested to see whether
PIPKIγ_i5 could associate with N-cadherin in vivo.I nH e L a
cells co-stained for PIPKIγ_i5 and N-cadherin, we observed
co-localization of PIPKIγ_i5 and N-cadherin at both cell–cell
contactsandwithincytoplasmic vesicles(Figure7B).Inaddition,
this targeting of PIPKIγ_i5 required kinase activity, as a kinase-
dead mutant (D316A) of PIPKIγ_i5 [17] localized diffusely
Figure 7 Localization of PIPKIγ_i5 is distinct from that of PIPKIγ_i2
HeLa cells expressing HA-tagged PIPKIγ_i5 were ﬁxed in paraformaldehyde and stained with
(A) anti-HA (green) and anti-talin (red) or (B) anti-HA (green) and anti-N-cadherin (NCD) (red)
antibodies. Yellow areas indicate co-localization of red and green immunoﬂuorescencesignals.
The inset ﬁgures are 175% zooms of the outlined area. The scale bar represents 10μm.
within cells and did not co-localize with N-cadherin (Figure 7B).
However,N-cadherin-basedcell–celljunctionswerenotdisrupted
in HeLa cells expressing PIPKIγ_i5 D316A, indicating that the
generation of PtdIns(4,5)P2 by PIPKIγ_i5 is not required for
the trafﬁcking of N-cadherin to the plasma membrane. Taken
together, these results are consistent with a functionally distinct
role for PIPKIγ_i5 in cadherin biology.
DISCUSSION
The popular nomenclature used for splice variants of PIPKIγ,
including those based on amino acid composition or apparent
molecular mass, suffers from ambiguity. Splice variants derived
from different species may contain similar exons and serve
identical biological functions, but often differ in amino acid
number and consequently their molecular mass. In addition,
PIPKIγ splice variants are post-translationally modiﬁed, which
alters their apparent molecular mass on gel electrophoresis. In the
present paper we have proposed and implemented a standardiz-
ation of nomenclature which conforms to the HUGO Genetic
Nomenclature Committee (http://www.genenames.org) and
HGVS (Human Genome Variation Society) (http://www.hgvs.
org) guidelines for transcripts and protein products respectively
of the PIP5K1C gene [40]. Continued use of this standardized
nomenclature will greatly simplify communication between
investigators who study PIPKIγ biology.
Alternative splicing of RNA transcripts is an efﬁcient cellular
mechanism that increases the diversity of its protein products,
thereby enhancing the overall functional speciﬁcity of a parti-
cular protein family. Much recent work has been devoted to
delineating the mechanisms by which the unique C-terminal do-
main of PIPKIγ_i2 is able to confer functional speciﬁcity on this
splice variant [1,3,4,41]. PIPKIγ_i2 functions by its C-terminus
associating with protein-targeting factors (i.e., talin, AP
complexes), which then target the kinase to focal adhesions or
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cell–cellcontactsrespectively.Oncetargetedtoitssiteoffunction,
PIPKIγ_i2 then generates PtdIns(4,5)P2, which regulates the
activities of proteins in the vicinity. Importantly, several proteins
that directly associate with PIPKIγ_i2 are also PtdIns(4,5)P2
effectors [1,3,4,41]. In the present paper we have described
two previously undeﬁned splice variants of the PIP5KIC gene,
PIPKI_i4 and PIPKIγ_i5, each of which contains a unique
C-terminaldomain.ItisveryprobablethattheseuniqueC-termini
direct the speciﬁc functions of PIPKIγ_i4 and PIPKIγ_i5 via the
association of each kinase with distinct protein-targeting factors
in a manner that parallels PIPKIγ_i2. By this mechanism, the
results presented here suggest that PIPKIγ_i4 and PIPKIγ_i5
mayﬁllspeciﬁcfunctionalroleswithinthenucleusandendosomal
transport system respectively.
Theexistenceofanuclearphosphoinositidesignallingpathway
that is independent of the cytoplasmic phosphoinositide cycle
has been established, albeit that it remains relatively poorly
deﬁned [24]. Several nuclear phosphoinositide kinases have been
identiﬁed, including another type-I PtdIns4P 5-kinase, PIPKIα
[20,24]. Recently, the PtdIns(4,5)P2 generated by PIPKIα at
sites of concentrated pre-mRNA processing factors known as
nuclear speckles was shown to regulate the activity of the nuclear
poly(A) polymerase Star-PAP [22,37]. Interestingly, our data
indicates several striking parallels between PIPKIα and our
newly discovered PIPKIγ_i4 splice variant. First, endogenous
PIPKIγ_i4 was found in both the nuclear and cytoplasmic
fractions of HeLa cells and also co-localizes with nuclear-speckle
markers, both in a manner similar to PIPKIα [20]. However,
endogenous PIPKIα, but not PIPKIγ, was detectable in Star-
PAP immunoprecipitates [22]. Moreover, another PtdIns(4,5)P2-
generating enzyme, PIPKIIβ, targets to nuclear speckles and
also does not associate with Star-PAP [22], which supports
the hypothesis that there are several discrete pools of nuclear
PtdIns(4,5)P2 that are generated by PIPKIγ_i4, PIPKIα or
PIPKIIβ.Inotherwords,thespeciﬁctargetingofthesekinasesand
theirassociationwithauniquesubsetofproteinsallowseachtoﬁll
a distinct functional niche in nuclear phosphoinositide signalling
pathways.
Secondly,itisimportanttonotethatPIPKIγ_i4isnotvisiblein
the nucleus upon overexpression, a localization phenotype that is
identicalwiththatofoverexpressedPIPKIα [20,22].However,en-
dogenous PIPKIα and PIPKIγ_i4 have been observed in both the
cytoplasm and the nucleus, which leads us to speculate that
the nuclear targeting of these kinases must be regulated in some
manner. It is possible that post-translational modiﬁcation of the
unique C-terminus of PIPKIγ_i4, or interaction of a nuclear-
targeted protein with this sequence, could modulate its nuclear
entry.AsobservedinFigure5(C),PIPKIγ_i4appearsasadoublet
in the nuclear, but not in the cytosolic, fraction of HeLa cells.
Therefore, nuclear PIPKIγ_i4 could be modiﬁed as a signal
for nuclear retention or functional speciﬁcity within a nuclear
subdomain. However, evidence supporting these speculations is
lacking, and further investigation is required to determine the
method of import as well as the potential nuclear functions of
PIPKIγ_i4.
Interestingly,thePIPKIγ_i3splicevariantidentiﬁedbyGiudici
et al. [33] shares 75% sequence identity with the ﬁrst 20 amino
acids of the PIPKIγ_i5 C-terminus. In agreement with our data,
Guidicietal.reportedthatPIPKIγ_i3localizedtovesicle-likeand
punctuatecytoplasmicstructureswhenexpressedinnon-neuronal
cells, where they also observed modest co-localization with
vesicular markers [33]. However, as the splice variant identiﬁed
byGiudicietal.seemstobelimitedtomouseneurons,wepropose
that the much more ubiquitous human PIPKIγ_i5 could serve to
perform similar biological functions in non-neuronal cells.
The role of phosphoinositides in the regulation of the
endosomal network has been well deﬁned for 3
 -phosphorylated
polyphosphoinositides [42–44], but less is known about the role
of PtdIns(4,5)P2 in these signalling pathways. However, it is
probable that PtdIns(4,5)P2 may also be a potent regulator of
endosomal transport [45,46], and the targeting of PIPKIγ_i5
to endosomal compartments suggests that the generation of
PtdIns(4,5)P2 could regulate endosomal system function or even
transport between endosomal subdomains. As the type-I PIPKs
have been shown to phosphorylate 3-phosphoinositides in vitro
[3], an alternative explanation is that, given a certain subcellular
condition or protein interaction partner, the substrate preference
of PIPKIγ_i5 could be changed to utilize 3-phosphoinositides,
thereby generating lipid messengers in addition to PtdIns(4,5)P2.
However, this shift in PIPK substrate preference has not
yet been shown to occur in vivo in organisms other than
Schizosaccharomyces pombe [3].
The signiﬁcance of the sequence similarity between the talin
and AP complex binding/regulatory site that is present in the
C-terminus of PIPKIγ_i2, and its ‘sister’ sequence that is present
in the C-terminus of PIPKIγ_i5 cannot be overlooked. Our data
indicate that, in the light of this similarity, PIPKIγ_i5 does not
associate with talin or APs and is not targeted in a manner similar
to PIPKIγ_i2. Although both PIPKIγ_i2 and PIPKIγ_i5 co-
localize with cadherins, the mechanism by which PIPKIγ_i5
is involved in N-cadherin function likely differs from that of
PIPKIγ_i2. When kinase inactive PIPKIγ_i2 or PIPKIγ_i1
(which lacks a C-terminal tail) was expressed in polarized
epithelial cells, trafﬁcking of E-cadherin to the plasma membrane
was hindered [17], indicating that both kinase activity as well
as the unique C-terminus of PIPKIγ_i2 is required for efﬁcient
basolateral targeting of E-cadherin. HeLa cells expressing
PIPKIγ_i5 D316A showed no apparent inhibition of N-cadherin
trafﬁcking to cell–cell contacts, but co-localization of PIPKIγ_i5
and N-cadherin was lost. These data suggest that PIPKIγ_i5 po-
tentially regulates the post-endocytic trafﬁcking of N-cadherin
rather than its exocytosis. Since PIPKIγ_i5 is partially localized
at several types of endosomal compartments, this splice variant is
positioned to regulate the endosomal trafﬁcking of N-cadherin,
E-cadherin or other proteins at multiple steps within the
endosomal system. However, further study is required to resolve
thenatureoftheendosomalcompartmentatwhichPIPKIγ_i5and
N-cadherin co-localize, and to determine the extent of regulation
by PIPKIγ_i5.
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